Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Neurofibroma × Everolimus × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 57 Carcinoma, Renal Cell 33 Neoplasm Metastasis 31 Neoplasms 21 Neuroendocrine Tumors 17 Kidney Neoplasms 17 Prostatic Neoplasms 15 Recurrence 14 Head and Neck Neoplasms 13 Hodgkin Disease 11 Tuberous Sclerosis 10 Triple Negative Breast Neoplasms 10 Precursor Cell Lymphoblastic Leukemia-Lymphoma 10 Lymphoma, Mantle-Cell 10 Multiple Myeloma 9 Lymphoma, Large B-Cell, Diffuse 9 Colorectal Neoplasms 9 Brain Neoplasms 9 Waldenstrom Macroglobulinemia 8 Sarcoma 8 Pancreatic Neoplasms 8 Lymphoma 8 Leukemia, Lymphocytic, Chronic, B-Cell 8 Glioblastoma 8 Melanoma 7 Lymphoma, Follicular 7 Glioma 7 Carcinoma, Non-Small-Cell Lung 7 Carcinoma, Neuroendocrine 7 Stomach Neoplasms 6

Interventions

talimogene laherparepvec 1 peginterferon alfa-2b 1 nilotinib 1 mirdametinib 1 binimetinib 1 antineoplaston AS 2-1 1 antineoplaston A10 1 Vincristine 1 Temozolomide 1 Talaporfin 1 Sirolimus 1 Restraint, Physical 1 Ranibizumab 1 Radiosurgery 1 Photochemotherapy 1 Neurofibromin 1 1 Imatinib Mesylate 1 Everolimus 1 Elasticity Imaging Techniques 1 Deoxycholic Acid 1 Cryotherapy 1 Celecoxib 1 Aminolevulinic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02332902 2023-12-20

DCLNF1

The University of Texas Health Science Center, Houston

Phase 2 Completed

24 enrolled 4 charts

Neurofibroma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡